News Releases | Insmed Incorporated

Month Year

Email Alerts

Mar 22, 2010

Pharmaceutical Industry Veteran Nicholas LaBella Jr., MS, RPh, Joins Insmed as Chief Scientific Officer

Read more
Mar 15, 2010

Insmed Announces Fourth Quarter and Full-Year 2009 Financial Results

Read more
Mar 4, 2010

Insmed Regains NASDAQ Compliance

Read more
Mar 3, 2010

Insmed to Host Fourth Quarter and Full-Year 2009 Conference Call

Read more
Nov 6, 2009

Insmed Announces Financial Results for Third Quarter and Nine-Months Ended September 30, 2009

Read more
Oct 22, 2009

Insmed To Host Third Quarter 2009 Conference Call

Read more
Sep 16, 2009

Insmed Receives NASDAQ Deficiency Notice Relating to Minimum Bid Price

Read more
Aug 13, 2009

Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2009

Read more
Jul 31, 2009

Insmed to Host Second Quarter 2009 Conference Call

Read more
Jul 27, 2009

Insmed Provides Update on Supply of IPLEX(TM)

Read more
Jun 30, 2009

Insmed Announces Addition to the Russell 3000(R) Index

Read more
Jun 25, 2009

Insmed Announces Results of IPLEX(TM) Phase II Trial in Myotonic Muscular Dystrophy

Read more
Jun 15, 2009

Insmed CEO Resigns Due to Health Concerns

Read more
May 13, 2009

Insmed Announces First Quarter 2009 Financial Results

Read more
May 5, 2009

Insmed Regains NASDAQ Compliance

Read more
Apr 23, 2009

Insmed to Host First Quarter 2009 Conference Call

Read more
Apr 22, 2009

Insmed to Host First Quarter 2009 Conference Call

Read more
Mar 31, 2009

Insmed Completes Sale of Follow-On Biologics Platform to Merck & Co., Inc. for Gross Proceeds of $130 Million

Read more
Mar 30, 2009

Insmed Announces Agreement With IDIS to Manage Expanded Access Programs for IPLEX(TM)

Read more
Mar 25, 2009

Insmed Announces That NASDAQ Further Extends Temporary Suspension of Minimum Bid Closing Price Rule

Read more
Mar 11, 2009

Insmed Announces Fourth Quarter and Full-Year 2008 Financial Results

Read more
Mar 10, 2009

Insmed Announces FDA Issues Statement Regarding Position on Allowing Patients With ALS Access to IPLEX(TM) Under an IND

Read more
Feb 26, 2009

Insmed to Host Fourth Quarter and Full-Year 2008 Conference Call

Read more
Feb 12, 2009

Insmed Sells Follow-on Biologics Platform to Merck & Co., Inc. for Gross Proceeds of $130 Million

Read more
Jan 21, 2009

Insmed and Premacure Announce European Orphan Designation for IPLEX(TM) in Retinopathy of Prematurity in Infants

Read more

Show per page

Stay In The Loop

Want to stay up to date on our news, events, and filings? Set up your email alerts.

Investor Presentation

View the latest Insmed Investor Presentation

Download

Company

Our Global Company

Patients

Current Clinical Trials

Science

Therapies

Responsibility

Responsibility in Action

Press Releases

Company

Our Global Company

Patients

Current Clinical Trials

Science

Therapies

Responsibility

Responsibility in Action

Footer